Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese Pulmonary Vascular Disease Research Group
About this trial
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.
Eligibility criteria
Qualifiers
Age ≥18 years old
Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS & PUMC, Beijing, China
Disqualifiers
Patients without RHC
The quality of routine examinations and RHC cannot meet the requirement for further analysis
Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)
Trial design
Treatments tested in this trial
- Right heart catheterization
Treatment groups
2,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov